Search
spesolimab
Indications:
- treatment of generalized pustular psoriasis (investigational)
- reduces risk of pustular psoriasis flares [3]
Dosage:
- a single 900 mg intravenous dose
Adverse effects:
- hepatotoxicity
Mechanism of action:
- pharmaceutical monoclonal antibody that inhibits IL-36
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
dermatologic agent
References
- Bankhead C
Dramatic Improvement in Generalized Pustular Psoriasis With IL-36 Inhibitor.
Complete clearance of pustules in half of patients in 1 week with spesolimab.
MedPage Today December 23, 2021
https://www.medpagetoday.com/dermatology/psoriasis/96365
- Bachelez H, MChoon SE, Marrakchi S et al
Trial of Spesolimab for Generalized Pustular Psoriasis.
N Engl J Med 2021; 385:2431-2440
PMID: 34936739
https://www.nejm.org/doi/full/10.1056/NEJMoa2111563
- Morita A, Strober B, Burden AD, et al.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised
pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised,
placebo-controlled trial.
Lancet. 2023 Sep 19:S0140-6736(23)01378-8
PMID: 37738999
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01378-8/fulltext